BullFrog AI to Unveil New Precision AI Capability

Core Insights - BullFrog AI Holdings, Inc. is set to launch a new scenario-based decision engine aimed at enhancing pharmaceutical portfolio strategy and clinical trial design, leveraging artificial intelligence and machine learning to provide actionable insights from complex biomedical data [1][2] Group 1: New Product Launch - The new AI capability will enhance the existing platforms bfPREP™ and bfLEAP by adding a strategic decision layer, moving beyond traditional portfolio tools that rely on rigid scoring systems [2][3] - This decision engine will evaluate options using proprietary algorithms, identifying robust programs and those that succeed under specific conditions [2][3] Group 2: Industry Context - The life sciences and pharmaceutical sectors invest over $200 billion annually in research and development, facing a significant challenge with a 90% clinical trial failure rate [3] - Current strategic portfolio decisions are primarily based on manual scoring and spreadsheet tools, which limit flexibility in comparative judgments [3] Group 3: Unique Capabilities - The new technology will allow for comparisons of drug programs, indications, and trial designs without imposing arbitrary numerical scores, testing decisions against various explicit scenarios [6][7] - It aims to identify options that perform well across different strategic futures while maintaining portfolio diversity and highlighting clear leaders for risk mitigation [7]